Document:

Exhibit 10.1

 

SUBSCRIPTION AGREEMENT

 

The undersigned (the "Subscriber"),
desires to become a holder of common shares (the "Shares") of Shuttle Pharmaceuticals, Inc., a corporation
organized under the laws of the state of Maryland, having its principal place of business located at1 Research Court, Suite 450,
Rockville, Maryland 20850 (the "Company").

 

Accordingly, the Subscriber hereby agrees as
follows:

 

1. Subscription.

 

	 	1.1	The Subscriber hereby subscribes for and agrees to accept from the Company that number of Shares set forth in Section 10 of this Subscription Agreement (the "Agreement"), in consideration of $8.00 per share.  This offer to purchase is submitted in accordance with and subject to the terms and conditions described in this Agreement. The Subscriber acknowledges that the Company reserves the right, in its sole and absolute discretion, to accept or reject this subscription and the subscription will not be binding until accepted by the Company in writing.

 

	 	
        1.2

         
	The closing of the Subscription of Shares hereunder (the "Closing") shall occur immediately upon: (i) receipt and acceptance by the Company of a properly completed and executed Agreement; (ii) receipt of all funds for the subscription of shares hereunder; and (iii) receipt by the Company of a minimum number of subscriptions as determined by the Company in its sole discretion.

 

2. Purchase Procedure.  The
Subscriber acknowledges that, in order to subscribe for Shares, Subscriber shall deliver to the Company the full purchase price
in the amount set forth in Section 10 below by certified or other bank check or by wire transfer of immediately available funds,
representing payment in full for the Shares desired to be purchased hereunder, made payable to the order of the Company.
Subscriber acknowledges and agrees that the Company does not intend to consummate the sale of any Shares until it has
received subscriptions and payment for a minimum of 1,250,000 Shares ($10,000,000) and will maintain subscription proceeds in a
segregated account until such time. The escrow agent that will hold such funds is PNC Bank, N.A. If a minimum of 1,250,000 shares
is not sold within the time period established by the Company’s board of directors, the Company will terminate the offering
and all funds received will be refunded to Subscriber.

 

3. Representations and Acknowledgements
of Subscriber.  By executing this Agreement, the Subscriber makes the following representations, declarations,
acknowledgements and warranties to the Company, with the intent and understanding that the Company will rely thereon:

 

	 	3.1	Such Subscriber acknowledges the public availability of the Company's current prospectus. This prospectus is made available in the Company's most recent S-1 Registration Statement deemed effective on _______, 2017. This prospectus sets forth the terms and conditions of the offering of Common Stock (the “Offering”) and the risks associated therewith are described.

 

	 	3.2  	All information herein concerning the Subscriber is correct and complete as of the date hereof and as of the date of Closing.

 

	 	3.3  	If the Subscriber is purchasing the Shares in a fiduciary capacity for another person or entity, including without limitation a corporation, partnership, trust or any other entity, the Subscriber has been duly authorized and empowered to execute this Subscription Agreement and all other subscription documents.  Upon request of the Company, the Subscriber will provide true, complete and current copies of all relevant documents creating the Subscriber, authorizing its investment in the Company and/or evidencing the satisfaction of the foregoing.
	 	 	 
	 	3.4	In connection with the Offering, the Company intends to seek a listing of its common stock on a securities exchange registered with the Securities and Exchange Commission (SEC) under Section 6(a) of the Securities Exchange Act of 1934, as amended, such as the NASDAQ Capital Market (the act of achieving such listing or quotation, generally referred to hereafter as a “Public Listing”), but there can be no assurance that the Company will ever achieve a Public Listing (See Risk Factors – Risks Related to the Offering in the Prospectus). The Subscriber understands that until such time as the Company achieves a Public Listing of its Shares, a public market will not exist for the Shares and it may be difficult to sell the Shares purchased in this Offering.  No U.S. federal or state agency has made any finding or determination as to the fairness of the terms of this Offering. These securities have not been recommended or endorsed by any U.S. federal or state securities commission or regulatory agency.

  

     

     

    

 

4. Governing Law.  This
Agreement shall be governed by and construed in accordance with the laws of the State of ___________________, without regard to
principles of conflicts of law.

 

5. Counterparts; Severability.  This
Agreement may be executed in one or more counterparts.  If any provision of this Agreement shall be held invalid or unenforceable
in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this
Agreement or the validity or enforceability of this Subscription Agreement in any other jurisdiction.

 

6. Persons Bound.  This
Subscription Agreement shall, except as otherwise provided herein, inure to the benefit of and be binding on the Company and its
successors and assigns and on each Subscriber and its respective heirs, executors, administrators, successors and assigns.

 

7. Section Headings.  The section headings contained in this Agreement are inserted for purposes of convenience of reference only and shall not
affect the meaning or interpretation of this Agreement.

 

8. Notices.  Any
notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, telegraphed,
telexed, sent by facsimile transmission or sent by certified, registered or express mail, postage prepaid, to the address of each
party set forth in this Agreement.

 

9. CERTIFICATION.  THE
SUBSCRIBER CERTIFIES THAT SUBSCRIBER HAS READ THIS ENTIRE SUBSCRIPTION AGREEMENT AND THAT EVERY STATEMENT MADE BY THE SUBSCRIBER
HEREIN IS TRUE AND COMPLETE.

 

10. Ownership Information.  Please
print here the number of Shares to be purchased, the Purchase Price and the exact name(s) in which the Shares will be registered.

 

Number of Shares Purchased: ____________________________________________________________________

 

Purchase Price @ $8.00 per Share: $_______________________________________________________________

 

Purchaser Name(s): ___________________________________________________________________________

 

________________________________________________________________________

 

	 	 	Single Person
	 	 	 
	 	 	Husband and Wife, as community property
	 	 	 
	 	 	Joint Tenants (with right of survivorship)
	 	 	 
	 	 	Tenants in Common
	 	 	 
	 	 	Corporation or other organization
	 	 	 
	 	 	A Partnership
	 	 	 
	 	 	IRA

 

     

     

    

 

	 	 	 
	 	 	Tax-Qualified Retirement Plan
	 	 	 
	 	 	Trust

 

(i)          Trustee(s)/Custodian
 ________________________________________________________________

 

(ii)         Trust
Date  _________________________________________________________________________

 

(iii)        Name
of Trust ______________________________________________________________________

 

(iv)        For
the Benefit of:  ___________________________________________________________________

 

	_________	 	Other:

 

 

(Please explain)

 

Social Security or Tax I.D.:  __________________________________________________________________________

 

 

Street Address (If P.O. Box, include address for surface delivery
if different than residence)

 

	 	 	 
	City	State	Zip Code

 

Telephone Numbers:

 

	Home: 	(        )
	 	 
	Cell: 	(        )
	 	 
	Facsimile: 	(        )
	 	 
	Email:	____________________________________________________________________

 

[Signature Pages Follow]

 

     

     

    

  

Subscriber Signature Page

 

The undersigned, desiring
to subscribe for the number of Shares of Shuttle Pharmaceuticals, Inc. (the "Company") as is set forth above,
acknowledges that he/she has received and understands the terms and conditions of the Subscription Agreement attached hereto and
that he/she does hereby agree to all the terms and conditions contained therein.

 

IN WITNESS WHEREOF, the undersigned
has hereby executed this Subscription Agreement as of the date set forth below.

 

	Date and Signatures.	 	Dated:______________, 201_
	 	 	 
	Signature(s)	 	Print Purchaser Name (s)
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

(Each co-owner or joint owner must sign – names must be signed
exactly as listed under “Purchaser Name(s)”)

 

     

     

    

  

Company Counterpart Signature Page

 

ACCEPTED:

 

	SHUTTLE PHARMACEUTICALS, INC.	 	 
	 	 	 
	By:	 	 	Dated:  ____________, 201_
	 	Name:	 	 
	 	TitleExhibit 10.6

 

Execution Copy

 

SHUTTLE PHARMACEUTICALS, LLC AND POLA PHARMA
INC.

 

EXCLUSIVE OPTION AGREEMENT

      

This Agreement, executed on this 4 th day of
July   , 2016 (“Effective Date”), by and between, POLA PHARMA INC., a pharmaceutical company organized and
existing under the laws of Japan, with its principal office located in 8-9-5 Nishigotanda Shinagawa-ku, Tokyo 141-0031, JAPAN,
(hereinafter referred to as “POLA”) and Shuttle Pharmaceuticals, LLC, a Maryland (USA) limited liability company having
its principal place of business located at One Research Court, Ste. 450, Rockville, Maryland 20850 (“OPTIONEE”), defines
the terms of the confidential relationship between the aforementioned parties (hereafter referred to as the “Parties”
collectively or “Party” individually).

 

Recitals

 

POLA is the owner of certain
Patent Rights (as later defined herein) relating to the technology entitled “Doranidazole” which was invented in POLA
laboratories and POLA has the right to grant an option under said Patent Rights.

 

POLA desires to have the
Patent Rights developed and commercialized to benefit the public and is willing to grant an option hereunder.

 

OPTIONEE wishes to obtain
an exclusive Option to negotiate and acquire an exclusive license from POLA to Patent Rights to manufacture, use, sell and distribute
products derived therefrom and POLA is willing to grant to OPTIONEE such an Option in accordance with the provisions of this Agreement.

 

NOW, THEREFORE, in consideration
of the premises and the mutual promises and covenants hereinafter set forth, the Parties hereby agree as follows:

 

Article 1

 

		1.	Effective Date and Option Period

 

		1.1	This Agreement shall begin on the Effective Date and continue for a period of twelve (12) months
(the “Option Period”) unless the Option is exercised, in which case this Agreement will terminate at the end of the
stipulated negotiation period or upon execution of a license agreement, whichever occurs first. The effective Option Period may
be extended to eighteen (18) months by mutual written consent of the Parties unless otherwise mutually agreed by the Parties.

 

    	 	1	 

     

    

 

Execution Copy

 

Article 2

 

		2.	Definitions

 

		2.1	“Exclusive Option”
                                         means an Option under which certain rights are granted to OPTIONEE under this Agreement.

 

		2.2	“Confidential Information”
                                         shall refer to non-public information of any kind which is disclosed by the disclosing
                                         Party to the other Party for purposes within the scope of Patent Rights and commercialization
                                         of Invention/Patent Rights and/or this Agreement which is either (i) by appropriate marking
                                         identified as confidential and proprietary at the time of disclosure; (ii) if disclosed
                                         orally, is identified in writing within thirty (30) days as being confidential; or (iii)
                                         is of such a nature that a reasonable person familiar with the Invention/Patent Rights
                                         or the Agreement would consider it to be confidential or proprietary from the context
                                         or circumstances of disclosure.

 

		2.3	“Invention” means
                                         invention known as Doranidazole made by POLA employees

 

		2.4	“Option” has the
                                         meaning set forth in Section 3.1.

 

		2.5	“Option Field” means
                                         the use of Patent Rights for medical uses in humans

 

		2.6	“Option Period”
                                         shall mean the period as defined in Section 1.1

 

		2.7	“Option Territory”
                                         means the U.S.A.

 

		2.8	“Option Products”
                                         shall refer to and mean any and all tangible products and processes that are composed
                                         of, incorporate, employ, or are in any way produced by the practice of, the Inventions
                                         and/or Patent Rights, or which the manufacture, use, or sale of would constitute infringement
                                         of any Patent Rights in the Inventions.

 

		2.9	“Patent Rights”
                                         means any U.S. or foreign patent applications or patents listed in Exhibit A, or the
                                         equivalent of such applications including any substitutions, divisionals, continuations,
                                         continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations,
                                         extensions, supplementary protection certificates and the like, and any provisional applications,
                                         of any such patents or patent applications, and the Invention described and claimed therein.

 

		2.10	“Term” shall mean
                                         the period as defined in Section 5.1

 

    	 	2	 

     

    

 

Execution Copy

 

Article 3

 

		3.	Option for an Exclusive License

 

		3.1	POLA, grants to OPTIONEE the Exclusive Option, with POLA, to obtain an exclusive license to the
Patent Rights within the Option Field and the Option Territory for the duration of the Option Period (the “Option”).

 

		3.2	In consideration of the Exclusive Option licensed from POLA, OPTIONEE shall grant a royalty free,
fully paid up, perpetual non-exclusive license to use any and all, including but not limited to , data, results, information and
know how generated through any activities by OPTIONEE during the Option Period, for licensing, development or commercializing purpose
of Doranidazole in accordance with Section 4.6 of this Agreement.

 

		3.3	POLA shall have the right to market and offer, license, assign or transfer the Patent Rights in
the Option Field to any third party out of the Option Territory.

 

		3.4	Subject to Section 3.1, in order to exercise the Option, OPTIONEE must, no less than thirty (30)
days prior to the end of Option Period, notify POLA in writing that it is exercising its rights and that it has satisfied the following:
a) completion of feasibility studies set forth in Section 4.5 for clinical development and commercialization of Doranidazole in
the United States; b) raised sufficient funding for research and development plans for the Option Products, proposed product offerings,
marketing plans and sales projections, financing and expense projections, management team and future staffing plans and other business
and technical information normally contained in such a document.

 

		3.5	Upon exercise of the Option, the Parties
                                         shall execute within a reasonable period not to exceed thirty (30) days an exclusive
                                         license agreement (“License Agreement”), a draft copy for discussion
                                         purpose of which is appended as Exhibit B, granting OPTIONEE exclusive rights to make,
                                         have made, use, import, export, offer to sell and sell Option Products in the Option
                                         Field in the Option Territory. The Parties shall make best reasonable efforts to execute
                                         the License Agreement through the good faith discussions based on the foregoing draft
                                         on Exhibit B within such period. Such License Agreement shall include but not limited
                                         to the following provisions: license fees; royalty payments; fund-raising/financing milestones;
                                         diligence and milestone requirements, including performance benchmarks; the right to
                                         grant sublicenses; a commitment by OPTIONEE and any sublicensee to exert their best commercial
                                         efforts to rapidly introduce the licensed products into public use.

 

		3.6	OPTIONEE understands that if the U.S. Government sponsors any development of the Patent Rights
then it shall have certain rights relative thereto. This Option Agreement is explicitly made subject to the Government’s
rights under the applicable U.S. Government agreements, applicable law and regulation. In the event of any inconsistency between
the terms of this Agreement and the terms of such Government agreement, applicable law or regulation, the Government agreement,
applicable law or regulation will prevail.

 

    	 	3	 

     

    

 

Execution Copy

 

Article 4

 

		4.	Evaluation Procedure and Patent Expenses

 

		4.1	POLA hereby grants OPTIONEE a royalty free, internal use license during the Option Period to practice
the Patent Rights, such as through a government sponsored research grant award or feasibility studies agreed by both Parties and
set forth in Section 4.5, solely for the purpose of OPTIONEE’S internal evaluation of the Patent Rights in furtherance of
this Agreement.

 

		4.2	OPTIONEE shall have the right to evaluate Patent Rights and their market potential and submit a
grant and other funding applications for the commercialization of the Inventions and the Patent Rights.

 

		4.3	Upon execution of this Agreement, POLA shall provide OPTIONEE with the available English translations
of Investigator’s Brochure and CMC Part of CTD Module 2 of Doranidazole set forth in the Exhibit C for the evaluation by
OPTIONEE during the Option Period as the Confidential Information in accordance with Article 6 below. For the avoidance of any
doubt, the said translations shall be provided on “as is” basis and any additional translation necessary for OPTIONEE’S
evaluation shall be done by OPTIONEE at its cost.

 

		4.4	In case OPTIONEE needs the active pharmaceutical ingredient of Doranidazole (“API”)
for their evaluation, OPTIONEE may purchase API from POLA at US$20,000/kg on “as is” basis up to 10kg.

 

		4.5	During the Option Period, OPTIONEE
                                         shall make good faith efforts to evaluate the potential for developing the Inventions
                                         into commercial products in the Option Field including but not limited to pre-IND meeting
                                         with the FDA followed by conducting studies in case required by FDA for IND and the fund-raising
                                         activities (“Option Period Activities”). OPTIONEE shall provide to
                                         POLA a final copy of any grant applications at the time of its submission to any granting
                                         organization. OPTIONEE shall provide to POLA a written report of Option Period Activities
                                         on or before OPTIONEE exercises/does not exercise the Option precisely describing the
                                         results of the evaluations, including but not limited to, pre-IND meeting minutes, a
                                         summary of the fund-raising activities for the Invention, and descriptions of relevant
                                         business, legal, scientific, technical, research and development activities for an Option
                                         Product, and relevant analytical data developed, produced, created, or acquired by OPTIONEE
                                         as a result of due diligence on Inventions and Patent Rights in the Option Field (“Option
                                         Evaluation Report”).

 

    	 	4	 

     

    

 

Execution Copy

 

		4.6	The Option Evaluation Report shall remain the sole and exclusive property of OPTIONEE and be disclosed
to POLA for informational purposes only during the Option Period, subject to the rest of this Article 4 and Section 3.2. POLA and
OPTIONEE shall treat all such information as Confidential Information in accordance with Article 6 below. In the event OPTIONEE
exercises the Option and executes a license for the Patent Rights in the Option Territory, POLA shall have a right to use this
property without any fees out of the Option Territory after the Option Period on prior written notice to OPTIONEE. In the event
this Agreement is terminated as set forth in Sections 5.2, 5.3, 5.4 or 5.5, the Option Evaluation Report shall remain the sole
and exclusive property of OPTIONEE, provided that POLA shall have a right to use this property to a third party upon POLA’s
prior written notice to OPTIONEE without any fees in or out of the Option Territory. POLA shall be permitted to retain a single
copy of the Option Evaluation Report for its files, which shall be maintained in accordance with Articles 4 and 6.

 

		4.7	POLA shall be responsible for the preparation, filing, prosecution and maintenance of any and all
patent applications and patents included in Patent Rights. POLA shall consult with OPTIONEE as to the preparation, filing, prosecution,
and maintenance of all Patent Rights reasonably prior to any deadline or action and shall provide OPTIONEE with drafts of any material
filings in a reasonable amount of time in advance of the anticipated filing date and shall consider in good faith any comments
of OPTIONEE on such patent filings for the Patent Rights

 

Article 5

 

		5.	Term and Termination

 

		5.1	This Agreement shall commence on the Effective Date. Unless sooner terminated in accordance with
this Article 5, this Agreement shall expire upon the latest to occur of:

(a) end of the Option Period; or

(b) upon execution of a license agreement.

 

		5.2	In the event OPTIONEE does not exercise the Option or Parties cannot reach the agreement of terms
and conditions of License Agreement, this Agreement shall be terminated immediately.

 

		5.3	OPTIONEE may terminate this Agreement by giving thirty (30) days written notice to POLA.

 

		5.4	POLA may terminate this Agreement upon thirty (30) days written notice to OPTIONEE if OPTIONEE
breaches its obligations including but not limited to not fully conducting the Option Period Activities as planned or defaults
on its payment obligations under this Agreement.

 

		5.5	The Parties may mutually agree in writing to terminate the Agreement.

 

    	 	5	 

     

    

 

Execution Copy

 

		5.6	Sections 3.2, 4.6, 6.1, 7.4, 7.5 and any other clauses of this Agreement which by nature would
be required to remain in effect shall survive termination.

 

Article 6

 

		6.	Confidentiality

 

		6.1	The Parties agree to keep any Confidential Information related to this Agreement, including
without limitation, OPTIONEE’S business plan, the Option Evaluation Report, the Patent Rights and all information concerning
it and any other information or discussion between the Parties, confidential.

 

Article 7

 

		7.	Miscellaneous Provisions

 

		7.1	This Agreement shall be construed and the rights of the Parties determined in accordance with the
laws of the state of Maryland, USA without regard to choice of law provisions.

 

		7.2	No use of the name of POLA in any form of promotion or in connection with the sale of products,
processes, devices, or designs is permitted without prior written approval from POLA. No Party will issue any news release, public
announcement, advertisement, or any form of publicity concerning this Agreement and the Option Evaluation Report, without obtaining
the prior written consent from the other Party, which consent shall not be withheld unreasonably.

 

		7.3	All notices required or permitted to be given under this Agreement shall be in writing and shall
be deemed to have been sufficiently given for all purposes thereof when mailed by certified mail to the Party to be notified. All
notices shall be deemed to have been given when mailed as evidenced by the postmark at the point of mailing.

 

All notices and any correspondence
respecting this Agreement shall be addressed as follows:

 

If to POLA:

By Postal Service:

Ataru Kobayashi, Director

Business Development and R&D

POLA PHARMA INC.

8-9-5 Nishigotanda Shinagawa-ku,

Tokyo 141-0031, JAPAN

 

If to OPTIONEE:

 

    	 	6	 

     

    

 

Execution Copy

 

By United States Postal Service:

Anatoly Dritschilo, MD, CEO

Shuttle Pharmaceuticals, LLC

One Research Court, Suite 450

Rockville, MD 20850

 

		7.4	This Agreement constitutes the entire and only agreement between the Parties relating to an option
to acquire a license, and all prior negotiations, representations, agreements and understandings are superseded hereby. No agreements
altering or supplementing the terms hereof may be made except by written mutual agreement by the Parties.

 

		7.5	The relationship between POLA and OPTIONEE is that of independent contractors. POLA and OPTIONEE
are not joint ventures, partners, principal and agent, master and servant, employer or employee, and have no other relationship
other than independent contracting parties. POLA will have no power to bind or obligate OPTIONEE in any manner, other than as is
expressly set forth in this Agreement. Likewise OPTIONEE will have no power to bind or obligate POLA in any manner, other than
as is expressly set forth in this Agreement.

 

		7.6	If any provision of this Agreement is ultimately held to be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.

 

		7.6.1	Any delay in enforcing a Party’s right under this Agreement or any waiver as to a particular
default or other matter will not constitute a waiver of such Party’s rights to the future enforcement of its rights under
this Agreement, except only as to an express written and signed waiver to a specific matter for a specific period of time.

 

		7.6.2	This Agreement may be executed by the Parties in counterparts, each of which when so executed shall
be deemed to be an original, but all of which shall constitute one and the same agreement.

 

		7.6.3	UNDER NO CIRCUMSTANCES WILL ANY PARTY HERETO BE LIABLE TO ANY OTHER PARTY FOR INDIRECT, INCIDENTAL,
CONSEQUENTIAL, EXEMPLARY OR SPECIAL DAMAGES, OR FOR ANY DAMAGES FOR BUSINESS INTERRUPTION THAT MAY ARISE OUT OF THIS AGREEMENT
OR USE OF THE PATENT RIGHTS, WHETHER OR NOT FORESEEABLE AND WHETHER OR NOT A PARTY NOTIFIED ANY OTHER PARTY OF THE LIKELIHOOD OR
POSSIBILITY OF SUCH DAMAGE.

 

THE REST OF THIS
PAGE IS LEFT BLANK INTENTIONALLY.

SEE NEXT PAGE
FOR SIGNATURES.

 

    	 	7	 

     

    

 

Execution Copy

 

IN WITNESS WHEREOF, the Parties hereto have caused this
instrument to be signed in duplicate by their duly authorized officers.

 

	POLA PHARMA, INC.	 	SHUTTLE PHARMACEUTICALS, LLC
	 	 	 
	/s/ Ataru Kobayashi	 	/s/ Anatoly Dritschilo
	Ataru Kobayashi, Director	 	Anatoly Dritschilo, MD
	Business Development and R&D	 	CEO
	 	 	 
	July 7, 2016	 	7/7/2016
	Date 	 	Date

 

    	 	8	 

     

    

 

Execution Copy

 

Exhibit
A

PATENT RIGHTS

 

Doranidazole,
Hypoxic Sensitizer Technologies

 

“Pharmaceutical
composition”

 

	Application
    No.	 	Publication
    No.	 	Patent
    No.
	12/598044
    (2008/4/16)	 	2010-0130576	 	8258165
	13/365785(div)	 	2012-0136160	 	8202898
	13/365723(div)	 	2012-0136295	 	8258166

 

“Pharmaceutical
composition”

 

	Application
    No.	 	Publication
    No.	 	Patent
    No.
	12/523067
    (2008/1/17)	 	2010-0076042	 	8541459
	13/362527(div)	 	2012-0129905	 	8450356
	13/362545(div)	 	2012-0130148	 	8420687

 

“METHOD
FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE” (Method of Manufacturing)

 

	Application
    No.	 	Publication
    No.	 	Patent
    No.
	12/522926
    (2008/1/17)	 	2010-0004460	 	8030338

 

1.
A method for producing 1-(1-benzoyloxymethyl-2-hydroxyethyl)oxymethy1-2-nitroimidazole, comprising: (A)
reacting glycerin with a benzoylating agent to obtain 1-O-benzoylglycerin; (B) reacting 1-O-benzoylglycerin with
dimethoxymethane in the presence of a dehydrating agent to obtain 4-benzoyloxymethyl-1,3-dioxolane; and then (C) reacting 4
benzoyloxymethyl-1,3-dioxolane with 2-nitroimidazole or 2-nitro-1-trialkylsilylimidazole in the presence of a Lewis acid, to
obtain 1-(1-benzoyloxymethyl-2-hydroxyethyl)oxymethyl-2-nitroimidazole.

 

4.
A method for producing l-(1-hydroxymethyl-2-fluoro)ethoxymethyl-2-nitroimidazole, comprising: (D) subjecting the
l-(l-benzoyloxymethyl-2-hydroxyethyl)oxymethyl-2-nitroimidazole obtained by the method according to any one of claims 1 to
3, to substituted sulfonylation, fluorination, and then debenzoylation.

 

    	 	 	 

     

    

 

Exhibit
B

 

Draft EXCLUSIVE
LICENSE AGREEMENT

 

(To
be negotiated)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]